Translating recent advances in the pathogenesis of acute myeloid leukemia to the clinic.

Abstract excerpt

Despite FDA approval of nine new drugs for patients with acute myeloid leukemia (AML) in the United States over the last 4 years, AML remains a major area of unmet medical need among hematologic malignancies. In this review, we discuss the development of promising new molecular targeted approaches for AML, including menin inhibition, novel IDH1/2 inhibitors, and preclinical means to target TET2, ASXL1, and RNA...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Leukemia, Myeloid, Acute
• Share to Mutation